FGM-108 is under clinical development by FutureGen Biopharm Technology and currently in Phase II for Metastatic Pancreatic Cancer. According to GlobalData, Phase II drugs for Metastatic Pancreatic Cancer have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how FGM-108’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
FGM-108 overview
FGM-108 is under development for the treatment of advanced unresectable and metastatic solid tumors including, pancreatic cancer, gastrointestinal tumor, gastric cancer, adenocarcinoma of the gastroesophageal junction and cholangiocarcinoma. The drug candidate is a monoclonal antibody which acts by targeting claudin 18.2. It is administered through intravenous route.
FutureGen Biopharm Technology overview
FutureGen Biopharm Technology is a medical equipment company which is involved in manufacturing of surgical devices. The company is headquartered in Bejing, China.
For a complete picture of FGM-108’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
